WSD 0628
Alternative Names: WSD-0628Latest Information Update: 21 Jan 2024
At a glance
- Originator Wayshine Biopharma
- Developer Mayo Clinic
- Class Antineoplastics; Radiosensitisers; Small molecules
- Mechanism of Action Ataxia telangiectasia mutated protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Glioblastoma
Most Recent Events
- 17 Jan 2024 Phase-I clinical trials in Glioblastoma (Second-line therapy or greater, Recurrent) in USA (PO) (NCT05917145)
- 11 Oct 2023 Pharmacodynamics data from preclinical study in Solid tumors presented at the International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2023)
- 08 Jun 2022 Wayshine Biopharma plans to submit an IND to the US FDA for WD 0628 in H1 2022 (Wayshinne Biopharm pipeline, June 2022)